- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
NCI's Featured Clinical Trial involves patients with DLBCL
The National Cancer Institute's Featured Clinical Trial concerns patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma.
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients with Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin Lymphoma (CALGB-50303).
Patients with previously untreated Diffuse large B-cell lymphoma (DLBCL) will be randomly assigned to receive either R-CHOP or EPOCH-R for 6 to 8 cycles. NCI researchers believe that there may be three different subtypes of DLBCL that have varying patterns of gene expression.
- "Can EPOCH-R produce better clinical outcomes than R-CHOP for patients with DLBCL?"
- "Can we use gene expression profiling to determine prognostic molecular characteristics that will tell us which patients benefit most from these different regimens?”